64Cu-SARTATE not checked
Clarity Pharmaceuticals Ltd · 64Cu-MeCOSar-Octreotate · Cu-64 SARTATE
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “64Cu-SARTATE will be administered at a fixed administration dose, single bolus intravenous injection, peptide mass not exceeding 60µg.”In the company’s words, NCT04438304 on ClinicalTrials.gov
- Tested for
- Neuroendocrine Tumors, Neuroblastoma, Relapsed Neuroblastoma, Refractory Neuroblastoma
- Main trialPhase 2
- “The purpose of this study is to assess the performance of imaging agent 64Cu-SARTATE in participants with known or suspected Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NETs) as a potential new way to help diagnose NETs.”In the company’s words, NCT04438304 on ClinicalTrials.gov
- Other names
- 64Cu-MeCOSar-Octreotate · Cu-64 SARTATE · copper 64 SARTATE
Other drugs for Neuroendocrine Tumors
- CAM2029Camurus AB · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- RYZ101RayzeBio, Inc. · Phase 3
- CemiplimabRegeneron · Phase 3
- DarovasertibIDEAYA Biosciences · Phase 3
- FianlimabRegeneron · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 26 Nov 2024 | A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO) | |
| Phase 1/2Terminated | 24 Jan 2025 | 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026